Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

NCT03282240 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2670

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: QIV-HD
BIOLOGICAL: Licensed TIV-HD1
BIOLOGICAL: Investigational TIV-HD2

Sponsor

Sanofi Pasteur, a Sanofi Company